Question

A 65-year-old with HFrEF (EF 30%) on ACE inhibitor and beta-blocker remains symptomatic. eGFR 45 mL/min/1.73 m², K+ 4.6 mEq/L, BP 112/68 mm Hg. Which additional class improves mortality across EF ranges and is indicated?

Accepted Answer

SGLT2 inhibitor

Answer

Thiazolidinedione

Answer

Ivabradine

Answer

Digoxin

Answer

Non-dihydropyridine CCB

Practice question

A 65-year-old with HFrEF (EF 30%) on ACE inhibitor and beta-blocker remains symptomatic. eGFR 45 mL/min/1.73 m², K+ 4.6 mEq/L, BP 112/68 mm Hg. Which additional class improves mortality across EF ranges and is indicated?